 Psychiatric symptoms and cognitive deficit can be induced by MK-801.
A C C E P T E D M A N U S C R I P T
Introduction
Schizophrenia is a critical public health problem afflicting approximately 0.7% of the population worldwide (McGrath et al., 2008) . The symptoms of schizophrenia are classified into three domains: positive, negative, and cognitive (Carbon and Correll, 2014) . It is also characterized by prolonged course and high disability rate, which places a heavy burden on the family, healthcare system, economy, and society in general. Treatment of schizophrenia is a major challenge. For many years, the primary target of schizophrenia pharmacotherapy was antagonism of dopamine receptors.
While D2 antagonists have proven efficacy for treating specific symptoms, particularly psychosis (a positive symptom), they are usually ineffective for treating others, especially cognitive symptoms. This More recent research has focused on dysfunction of the glutamatergic system in schizophrenia pathogenesis and symptom expression, in particular hypoactivity of glutamatergic signaling through N-methyl-D-aspartate (NMDA) receptors (Coyle, 1996; Deakin et al., 1989; Mohn et al., 1999) . A central piece of evidence supporting this hypothesis is that NMDA receptor antagonists such as phencyclidine (PCP), dizocilpine (MK-801), and ketamine can induce a psychotic syndrome in healthy individuals that resembles schizophrenia and exacerbate symptoms in schizophrenic patients (Javitt and Zukin, 1991; Krystal et al., 1994; Lahti et al., 2001; Maia-de-Oliveira et al., 2015b; Malhotra et al., 1997) . Further, drugs regulating NMDA receptor activity have therapeutic effects on schizophrenia (Singh and Singh, 2011) . For example, the metabotropic glutamate 2/3 receptor agonist pomaglumetad improve patient symptoms (Kinon et al., 2015) . Based on this growing body of evidence, new schizophrenia drug therapies are being developed that target the glutamate pathway.
Animal models are valuable tools for investigating potential new therapeutic strategies for the treatment of schizophrenia symptoms (Issy et al., 2014) . NMDA receptor antagonists such as PCP, MK-801, and ketamine can mimic positive, negative, and cognitive symptoms of schizophrenia and so are widely used to establish schizophrenia animal models (Krystal et Thornberg and Saklad, 1996) . A number of recent animal studies have suggested that the nitric oxide (NO) donor sodium nitroprusside (SNP) can ameliorate NMDA receptor antagonist-induced psychiatric symptoms and cognitive deficits (Bujas-Bobanovic et al., 2000; Hurtubise et al., 2017; Issy et al., 2014; Kandratavicius et al., 2015; Maia-de-Oliveira et al., 2015b; Trevlopoulou et al., 2016; Wiley et al., 1997) . Similar findings were also found in clinical studies. Several clinical studies have reported that SNP displays antipsychotic activity and can improve cognitive deficits in schizophrenia patients taking antipsychotics (Hallak et al., 2013; Maia-de-Oliveira et al., 2015a ). Maia-de-Oliveira and colleagues reported that SNP also benefits patients with antipsychotic (clozapine)-refractory schizophrenia (Maia-de-Oliveira et al., 2014a) , but the exact mechanism of action is unclear.
As a nitric oxide (NO) donor, SNP may act through the glutamate NMDA receptor−NO−cyclic guanosine monophosphate (cGMP) pathway to influence targets regulated by NMDA receptor activation (Bernstein et al., 2005; Miuller and Schwarz, 2007) . After infusion, SNP is converted to NO, thereby bypassing brain NMDA receptor-induced activation of nitric oxide synthase (NOS) to directly elevate tissue nitric oxide levels. These findings suggest that SNP may act as a compensatory factor for NMDA receptor signaling pathways (Stone et al., 2016) . There is also evidence suggesting that SNP can directly normalize NMDA receptor function in schizophrenia as well as modulate the dopaminergic system through NO. (Gholampour et al., 2017; Lee and Kim, 2008; Maia-de-Oliveira et al., 2014b) A Behavioral tests were conducted between 8:00−18:00 under controlled temperature, humidity, and dim lighting. Rats were transferred to the experimental room 30 min before testing for adaptation to the new 
Rotarod Test
The rotarod device (Rota Rod R03-1, Shanghai Xin soft Mdt InfoTech Ltd) consisted of a metal frame with a motorized rotating assembly of rods. Rods were chosen to provide a walking surface rather than the single continuous surface of commercially available rotarod units. Two large clear Plexiglas discs were positioned on each side of the frame. The walking area of the apparatus consisted of 18 rungs (1-mm stainless steel rods) arranged in a cylindrical fashion. A control box located adjacent to the device was used to adjust the speed and direction of rotation (forward or reverse). Rotational speed ranged from 0 to 30 rpm. The animal's task was to walk on the rungs while they rotated. The rationale for using this version of the rotarod test is that the grip strength required for the single rod version decreases when blood pressure is below normal, and SNP is a
To establish criteria for evaluating performance on this task, 10 rats were assessed at various speeds of rotation. Each animal was placed on the rungs and allowed to remain stationary at 0 rpm for 10 s, after which the speed was increased to 5 rpm for a maximum of 2 min. Rats were then tested at 5, 10, 15, 25, and 30 rpm. Based on the preliminary testing, 25
rpm was determined to be the best rotational speed for examination of SNP effects on motor function.
24 rats were randomly divided into 4 groups and each was trained for 30 min before the formal experiment. The rat was allowed to remain stationary for 10 s at 0 rpm and then rotational speed was increased linearly to 25 rpm in 30 s. The rat was required to remain on the device at this speed for 3 min. A trial ended if the rat fell completely off the rungs or gripped the device and spun around for two consecutive revolutions without attempting to walk on the rungs (Hamm et al., 1994) . Each rat received three trials, and the mean duration (in second) on the device was recorded.
Then rats were injected IP with SNP at 2.5, 3, 4, or 5 mg/kg according to group. Ten minutes after injection, the rotarod test was conducted as described above.
Preliminary open field test
The open field test is frequently used to detect an animal's (mainly rats and mice) behavioral and emotional characteristics including exploratory relative to the periphery reflects anxiety-like behavior (Bath et al., 2012) . After the test was completed, the rats were placed into the feeding cage, and the arena cleaned of feces. The walls and floor were then cleaned with a disposable clean towel soaked in 75% alcohol to prevent residual scents from influencing the behavior of the next test animal. These studies identified 2.5 mg/kg as the most suitable SNP dosage for the next trial.
Part 2 Model preparation and Intervention

Drug treatment and grouping
All of the solutions were freshly prepared and handled as described for preliminary experiments. MK-801 was dissolved in 0.9% sterile saline.
96 rats were randomly divided into 4 groups, 24 rats in each group, and participated in open field test, PPI, EPM and Y -maze tests respectively.
24 rats were randomly divided into 4 groups of 6 as follows: group1-saline, group2-SNP, group3-MK-801, group4-SNP+MK-801. The rats were separately injected IP with isovolumetric vehicle (NaCl 0.9%) or 2.5 mg/kg SNP (a dose based on a previous study (Bujas-Bobanovic et al., 2000) and results of the rotarod test and preliminary open field test) 5 min prior to MK-801 administration (0.4 mg/kg). Behaviors were assessed 10 minutes later.
Behavioural analysis
Behavioral testing included open field test, PPI, elevated plus-maze, and Y maze. The drug treatment and grouping of each test were carried out as above. And 10 minutes later, behaviors were examined.
Open field test
Locomotor activity and anxiety-like behavior of rats were measured in the open field using the SMART 2.5 system as described.
Prepulse Inhibition
Prepulse inhibition (PPI) of the acoustic startle response is a behavioral
paradigm used to investigate deficits in attentional processing (Wiley et al., 1997) . The degree of PPI reflects integration of sensory and motor processes in the brain, and has been shown to be disrupted in patients with acute schizophrenia. In animals, a similar deficit can be produced by administration of a noncompetitive NMDA receptor antagonist. PPI is frequently used to predict the antipsychotic activity of compounds and in pharmacological studies testing pro-psychotic activity (Geyer et al., 2001) . In this experiment, PPI was induced by acoustic startle. Rats were placed in the startle chambers for a 5-min adaptation period. A continuous acoustic signal provided a background white noise level of 65 dB, which was interrupted by stimulus presentations. The startle pulse was a burst of white noise at 120 dB for 40 ms and the prepulse a pure tone at 75, 80, or 85 dB for 20 ms. The interval between the onset of the prepulse and the startle pulse was 100 ms. Each startle session consisted of 50 trials with an average intertrial interval of 15 s. The amplitude of the startle response following a prepulse was compared to that for the startle pulse alone. The equipment was cleaned and disinfected after every session as described.
Elevated plus maze test
The elevated plus maze test is a common experimental paradigm used to measure the anxiety level of rodents due to it methodological simplicity and non-invasive nature. In the present study, the elevated plus maze system. After each test, the equipment was cleaned as described for the open field test.
Y maze test
The Y maze test is mainly used for discrimination learning, working memory, and reference memory tests. The Y maze consists of three identical arms positioned at 120. A movable partition plate in the center creates different geometric patterns and each arm has associated visual cues. The three arms were randomly divided into a novel arm, start arm, and other arm. Spatial memory is assessed by the time spent in the target arm and number of entries into the target arm. The basic advantages of the Y maze are that it exploits a rodent's natural tendency for exploration of a new environment without requiring any motivational or adverse stimuli. The experiment was divided into 2 stages, training and testing. In the training period, the novel arm was blocked, and the rats were allowed
to freely explore the other 2 arms for 10 min. At the end of the training session, the rat was put back in the home cage. Two hours later, the test phase was conducted in which the novel arm, start arm, and other arm were all open and the rat allowed to explore each freely. A camera was placed 1.5m above the maze to record the time spent and frequency of arm entries over 5 min. The time spent in the novel arm and the number of novel arm entries were used as indices of memory performance.
Statistical analysis
The data are presented as means ± standard deviations and were analyzed with SPSS 20.0 (SPSS Inc., Chicago, IL, USA). Student's t test and one-way ANOVA were used for the data analysis, according to the nature of the data. All results are two-sided, and the level of significance is α = 0.05.These photographs were performed using GraphPad prism software, version 6.
Results
Dosage of SNP
In this present study, the SNP dose was based on a previous study and the 
Effects of SNP on MK-801-induced abnormalities in PPI
There were significant differences in different prepulse intensity between (Figure 3) .Therefore, SNP pretreatment did not reverse the PPI disruption induced by MK-801. 
Effects of SNP on MK-801-induced abnormalities in Elevated plus maze test
Effects of SNP on MK-801-induced abnormalities in Y maze test
In Y maze test, compared with saline, the number of novel arm entries was significantly lower in the MK-801 groups(P<0.05), suggested that the schizophrenia model was established.
The number of novel arm entries was significantly lower in the SNP+MK-801 groups compared to the saline group(P<0.05), while there was no significant difference between SNP and saline groups(P>0.05).
There was no significant difference in % time in the novel arm among groups(df=2,20,F=1.374,P=0.279)( Figure 5 ). And that has power to detect an effect size of 0.783 used by Gpower software.Therefore, the
cognitive deficit induced by MK-801 was not reversed by SNP pretreatment.
Discussion
Conventional antipsychotics are largely ineffective against cognitive deficits, and cognitive dysfunction is a major predictor of long-term poor outcome (Marder and Fenton, 2004) . Several recent studies have reported that the NO donor SNP blocks NMDA receptor antagonist-induced psychiatric symptoms and cognitive deficits in rats (Bujas-Bobanovic et al., 2000; Hurtubise et al., 2017; Issy et al., 2014; Kandratavicius et al., 2015; Maia-de-Oliveira et al., 2015b; Trevlopoulou et al., 2016; Wiley et al., 1997) . In the present experiments, we examined the effects of SNP pretreatment on MK-801-induced anxiety and cognitive deficits but found no benefits at a dose that did not interfere with motor activity.
MK-801 induced psychiatric symptoms and cognitive deficit
Glutamate is the main excitatory neurotransmitter in the brain and glutamatergic neurons account for between 60% and 80% of all metabolic activity in the non-stimulated cerebral cortex (Stone, 2011) . There is growing evidence for dysregulation of the glutamatergic system in schizophrenia (Lin et al., 2012; Miuller and Schwarz, 2007) , suggesting that drugs targeting the glutamate pathway may be effective as monotherapy or as adjunct treatment. Indeed, the greater efficacy of clozapine compared to other antipsychotics and its effectiveness in otherwise treatment-resistant patients has been linked to its glutamatergic actions (Javitt et al., 2005) .
Glutamate acts on two main subtypes of receptors, metabotropic and (Javitt, 2007; Morgan and Curran, 2006; Singh and Singh, 2011) . MK-801 is a noncompetitive NMDA receptor antagonist that can induce a schizophrenia-like psychotic syndrome (Javitt and Zukin, 1991; Krystal et al., 1994; Lahti et al., 2001; Maia-de-Oliveira et al., 2015b; Malhotra et al., 1997) and mimic positive, negative, and cognitive symptoms in rats (Krystal et al., 2005; Thornberg and Saklad, 1996) . In the present study, MK-801 induced a complex behavioral MK-801 also caused a significant impairment of PPI. In the Y maze test, however, we found no significant effect, possibly because the effects of MK-801 decay before the final testing phase.
SNP as a donor of NO
Nitric oxide is an intracellular and intercellular messenger critical for numerous physiological and pathophysiological processes, including maintenance of normal cardiovascular function, memory formation, responses to neurotrauma and stroke, and tolerance to drugs of abuse.
Nitric oxide is also implicated in schizophrenia through effects on both dopaminergic and glutamatergic transmitter systems. However, the association of NO with schizophrenia and the effects of NO manipulation on schizophrenia symptoms have been inconsistent across studies. Some studies have reported that NO metabolites are low in the plasma and cerebrospinal fluid of patients (Lee and Kim, 2008; Nakano et al., 2010; Ramirez et al., 2004) , indicating NO pathway hypofunction, while other studies have reported elevated NO(Yilmaz et al., 2007) and NO metabolites (Herken et al., 2001) in red blood cells of patients. There are reports that antipsychotic drugs acting on molecules downstream of the NMDA receptor, such as NO, can treat the psychiatric symptoms by compensating for receptor hypofunction (Gholampour et al., 2017) .
SNP has been used clinically as a quick-and short-acting vasodilator
for severe hypertension (Page et al., 1955) . The main mechanism of action appears to be through the release of NO, leading to smooth muscle relaxation. In addition, SNP can promote increased cerebral perfusion and other vascular effects modulated by NO, and it has been suggested that schizophrenia patients exhibit cerebral hypoperfusion (Pinkham et al., 2011) .
Therefore, NO may act by enhancing general metabolic activity. While a number of animal and clinical studies suggest that SNP is effective against psychiatric symptoms and cognitive deficits (Bujas-Bobanovic et al., 2000; Hallak et al., 2013; Hurtubise et al., 2017; Issy et al., 2014; Kandratavicius et al., 2015; Maia-de-Oliveira et al., 2015a; Maia-de-Oliveira et al., 2015b; Trevlopoulou et al., 2016; Wiley et al., 1997) , the mechanisms of action are unclear. In addition to NO generation and ensuing cGMP production, SNP may also have a direct action at the NMDA receptor.
SNP did not block MK-801-induced psychiatric symptoms and cognitive deficits
For many decades, it was assumed that schizophrenia results from chronic dopamine hyperactivity. However, dopamine antagonists are relatively ineffective in alleviating some symptoms of schizophrenia, and no available antipsychotics acting on dopamine receptors consistently alleviate the cognitive symptoms of schizophrenia. However, when SNP was administered as an adjunct treatment to patients with schizophrenia, psychiatric symptoms and cognitive impairments were reduced (Hallak et al., 2013; Maia-de-Oliveira et al., 2015a; Maia-de-Oliveira et al., 2015b) . Similar results were 
5.Conclusion
Pretreatment with SNP (2.5 mg/kg) did not reduce MK-801-induced behavioral abnormalities or cognitive impairments, inconsistent with previous studies using PCP to model schizophrenia symptoms in rodents.
These results suggest that the mechanisms underlying MK-801-induced symptoms are at least partially distinct from those responsible for PCP-induced effects. Further research is required to expand the range dosage of SNP and test its efficacy as adjunct treatment on multiple schizophrenia models.
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